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Abstract
Aims There is a continuing search for new treatment op-
tions in patients who suffer from refractory angina pectoris
to improve quality of life. Several studies have recently
demonstrated promising results by stimulating angiogenesis
using extracorporeal shockwave therapy in these patients.
The purpose of this study is to quantitatively analyse the
effect of extracorporeal shockwave therapy on myocardial
perfusion in patients with refractory angina pectoris.
Methods We included 15 patients with NYHA class 3–4 of
whom 8 patients underwent baseline and follow-up cardiac
magnetic resonance imaging (CMR). All patients received
9 shockwave treatments of their ischaemic zone over a pe-
riod of 3 months.
Results Quantitative analysis of myocardial perfusion using
CMR revealed no significant improvement of myocardial
perfusion after treatment (0.80 ± 0.22 vs 0.76 ± 0.31; p =
0.42). However, the total group of 15 patients did experi-
ence a significant improvement in NYHA class (p = 0.034)
and reduction of nitroglycerin use (p = 0.012).
Conclusion Although treatment with extracorporeal shock-
wave was associated with an improvement in NYHA class,
we could not observe an improvement in myocardial is-
chaemic zone and perfusion with CMR. To unravel the ex-
act mechanisms of shockwave treatment, more in vitro and
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animal studies as well as larger (placebo-controlled) studies
are required.
Keywords Shockwave therapy · Quantitative analysis ·
Myocardial perfusion · Refractory angina pectoris ·
Cardiac MRI
Introduction
Despite maximal pharmacotherapy and revascularisation
procedures there is a growing number of patients who
suffer from refractory angina pectoris, with an estimated
incidence between 5 and 10 % and a 9-year mortality of
almost 30 % [1, 2]. As a result, there is a continuing
search for new treatment options for this specific patient
group. Several therapeutic interventions have been tried
to improve quality of life (thoracic epidural analgesia [3],
transcutaneous electrical nerve stimulation [4], spinal cord
stimulation [5]) and/or reduce myocardial ischaemia (en-
hanced external counterpulsation [6], percutaneous trans-
myocardial laser revascularisation [7], and gene therapy
[8]).
Recently, a new noninvasive treatment strategy stimulat-
ing angiogenesis has gained attention [9–11]. Extracorpo-
real shockwave therapy uses high-intensity acoustic pulsed
waves to stimulate angiogenesis. Based on a pre-clinical
study the intensity used is approximately 10 % of the inten-
sity used with lithotripsy [9]. In an in vivo pig model with
chronic occlusion of the left circumflex coronary artery,
local application of shockwave therapy improved left ven-
tricular ejection fraction, wall thickening fraction and my-
ocardial blood flow in the ischaemic region after 4 weeks
compared with non-treated pigs [9]. Furthermore, histol-
ogy also showed an increase in capillary density in the
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Fig. 1 Myocardial perfusion of all 12 segments per region (base, mid or apex) by calculation of the maximal relative upslope (yellow lines),
corrected for baseline signal intensity and the arterial input by the upslope of the blood pool curve (red line); a steeper yellow line means a better
myocardial perfusion
treated pigs as well as an upregulation of vascular endothe-
lial growth factor (VEGF) mRNA expression.
The first small studies in humans show promising re-
sults based on the Canadian Cardiovascular Society class,
exercise testing and qualitative analysis of SPECT images
[11–15]. However, no quantitative analysis has been per-
formed to objectively measure the myocardial blood flow
in the treated ischaemic zone.
Therefore, we initiated this study to quantitatively ex-
amine the effect of shockwave therapy on the ischaemic
zone in patients with refractory angina pectoris. We hy-
pothesise that shockwave therapy may improve New York
Heart Association (NYHA) class by decreasing the size of
the ischaemic zone and increasing myocardial blood flow in




Patients of 18 years or older suffering from refractory
angina pectoris where included in the study. Refractory
angina pectoris is defined as having angina pectoris NYHA
class 3–4 based on documented ischaemia without any
possible revascularisation option left, either PCI or CABG,
under a maximum tolerable dose of medication. Patients
were excluded from the study when they suffered from
severe heart valve disease, intraventricular thrombus, a ma-
lignancy in the area of treatment, chronic lung disease
(including emphysema and pulmonary fibrosis), a myocar-
dial infarction in the 3 months prior to the start of the study,
had a contraindication for undergoing CMR, or when the
patient was pregnant.
The protocol was approved by the medical ethics com-
mittee of the VU University Medical Center and all patients
provided written informed consent.
CMR
After refraining from intake of competitive antagonists of
adenosine in the 24 hours prior to examination, CMR was
performed on a clinical 1.5 Tesla scanner (Avanto, Siemens,
Erlangen, Germany) using a phased-array cardiac receiver
coil. All images were ECG gated and acquired during mid-
expiratory breath-holds of 10 to 15 seconds, depending on
the heart rate.
Using the four-chamber long-axis cine in the end-sys-
tolic phase, 3 short-axis slice positions were determined
for myocardial perfusion imaging, at 25, 50 and 75 % of
the distance between the mitral valve annulus and the apex.
Prior to imaging, patients received intravenous adenosine
at a rate of 140 µg/kg/min for 3 minutes. Image acquisi-
Neth Heart J (2016) 24:319–325 321
Table 1 Sequence parameters for myocardial perfusion with CMR
Sequence – Parameter
Steady-state free precession cine imaging
Spatial resolution (frequency encoding dir.) 1.3–1.6 mm
Spatial resolution (phase encoding dir.) 1.8–2.2 mm
Slice thickness 5.0 mm
Slice gap 5 mm
Flip angle 75°
Field-of-view size 360–400 mm
Matrix size 256 × 256
Percentage phase field of view 80–90 %
Echo time 1.54 ms
Temporal resolution 34–38 ms
First-pass perfusion – single-shot saturation recovery gradient echo
Spatial resolution (frequency encoding dir.) 2.2–2.5 mm
Spatial resolution (phase encoding dir.) 2.2–2.5 mm
Slice thickness 8.0 mm
Slice gap 10–17 mm
Field-of-view size 360–400 mm
Matrix size 160 × 160
Percentage phase field of view 100 %
Time of repetition 154.8 ms
Echo time 1.0 ms
Flip angle 18°
Acceleration technique Echo planar imaging
Duration 50 cardiac cycles
T1-weighted inversion recovery gradient echo
Spatial resolution (frequency encoding dir.) 1.3–1.6 mm
Spatial resolution (phase encoding dir.) 1.6–1.9 mm
Slice thickness 5.0 mm
Slice gap 5.0 mm
Flip angle 25°
Field-of-view matrix 256 × 256
Percentage phase field of view 80–95 %
Time of repetition 1 x RR interval
Echo time 4.4 ms
Inversion time 250–400 ms
tion was initiated simultaneously with the administration of
a 0.1 mmol/kg bolus of a gadolinium-based contrast agent
(Magnevist, Schering AG, Berlin, Germany) at a rate of
3 ml/sec. Images were acquired at the 3 aforementioned
levels during each cardiac cycle, for a total duration of
50 cardiac cycles. Adenosine infusion was discontinued
immediately after the images were obtained.
At least 10 minutes after stopping adenosine infusion
and myocardial perfusion acquisition, resting myocardial
perfusion imaging was performed, using the same se-
quence parameters and contrast dose (total cumulative dose
0.2 mmol/kg). The sequence parameters used for cine and
myocardial perfusion imaging are mentioned in Table 1.
Shockwave treatment
Shockwave therapy was applied using the Cardiospec
(Medispec, Germantown, Maryland). The location of the
ischaemic zone was detected by consensus of 2 experi-
enced observers based on visual inspection of CMR, using
regional function. This area was translated into the 16-
segment model of echo and divided into three parts. In
order to make sure we covered the entire ischaemic zone
we enlarged the treatment area. Therefore, more regions
were treated than located on CMR. The treatment protocol
covered a total period of 9 weeks in which patients were
treated in weeks 1, 5 and 9. During each treatment week
the patient visited the outpatient clinic 3 times, resulting in
a total of 9 treatments.
Patients were positioned in a supine position and con-
nected to continuous ECG monitoring. An S3 ultrasound
probe, which was linked to a Sonos 4500 (Philips, Best,
the Netherlands) and connected to the Cardiospec, was po-
sitioned on the chest of the patient so that the ischaemic
treatment zone was located in the centre of the ultrasound
image. The depth of the ischaemic zone was measured us-
ing a caliper on the ultrasound machine. Based on these
measurements a balloon with a shockwave electrode inside
and attached to the Cardiospec was placed on a patient’s
chest at the appropriate position. Using an ellipsoid reflec-
tor inside the balloon enabled us to focus the shockwave
with the right intensity to any possible depth. The intensity
used was based on pre-clinical studies where an optimal
dosage-effect relation was shown at approximately 10 % of
the intensity used with lithotripsy, as was mentioned earlier
[9]. Since the depth and location of the machine could be
adjusted we were able to apply the same amount of energy
to two remote distinct treatment zones. The balloon was in-
flated with saline water (5 % NaCl) until a good connection
with the skin was achieved. Prior to inflation of the balloon
a large amount of gel was applied to the skin in order to
prevent any air becoming trapped between the skin and the
balloon. Once installed, a total of 100 shocks per spot were
applied. The amount of spots treated during a session de-
pended on the size of the ischaemic zone, with every spot
covering an area of approximately 1 by 1 cm.
Analysis and definitions
Analysis was performed off-line using dedicated software
(MASS v.5.1 2010-EXP beta, Medis, Leiden, the Nether-
lands) by consensus of 2 experienced observers. All anal-
yses were performed on short-axis images with a 16-seg-
mental distribution of the myocardium. Using the cine im-
ages, myocardial volumes during the end-diastolic and end-
systolic phase were calculated. From the volumes, stroke
volume and ejection fraction were calculated. The location
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ESV 81.9 ± 40.2 86 ± 41.4 0.36
EF 51.8 ± 15.2 51.5 ± 16.5 0.89
MPRi treated zones 0.80 ± 0.22 0.76 ± 0.31 0.42
MPRi total 0.79 ± 0.11 0.72 ± 0.24 0.40
EDV end-diastolic volume, ESV end-systolic volume, EF ejection frac-
tion, MPRi myocardial perfusion ratio index (relative upslope of stress
to rest, normalised to LV input)
of the treatment zone was based on visual inspection by
consensus of 2 experienced observers.
Myocardial perfusion was evaluated quantitatively by
calculation of the maximal relative upslope [%], using the
maximum upslope [au·s–1] of the myocardial signal-inten-
sity-versus-time curves and by correcting for baseline signal
intensity [au] and the arterial input by the upslope of the
blood pool curve [au·s–1] (Fig. 1). As mentioned above, in
order to make sure we treated the entire ischaemic zone
we enlarged the treatment area, resulting in treatment of
healthy segments. To reduce the effect of these treated
healthy segments and to reduce the effect of artifacts on
analysis we divided the 3 short-axis views (base, mid and
apical) into 12 segments per axis. Previous studies have
already proven the relative upslope to be an accurate and
reproducible parameter for quantitative perfusion analysis
[16–18].
Questionnaire
Prior to the start of shockwave treatment all patients were
asked to answer the Seattle Angina questionnaire to esti-
mate NYHA class, the use of nitroglycerin and the fre-
quency of angina pectoris. The same questionnaire was
used 3 months after final treatment during follow-up CMR.
Statistical analysis
Categorical data are presented as frequencies (percentage),
and continuous data as mean ± SD. Comparisons between
means of groups were performed using Student’s T-test
(2 groups) and the Wilcoxon signed-rank test in case of
ordinal variables. Obtained data were analysed using SPSS
21.0 (Chicago, USA).
Results
Between March 2009 and November 2011, a total of 15 pa-
tients underwent shockwave therapy, of whom 8 underwent
serial baseline and follow-up CMR. Due to claustrophobia
(n = 1), obesity (n = 1) or an implantable device (n = 5),
the remaining 7 patients were not analysed using CMR. Of
these 8 patients, 6 had a CABG and 1 or more PCIs in
their medical history and 2 only PCIs. All patients had 1
or more chronic total occlusion of their native system at
inclusion. In 3 of these patients all 3 vessels of the na-
tive system had a chronic total occlusion and in 2 out of
8 patients there were 2 chronic total occluded vessels. In-
terestingly, only 2 of these 8 patients had collateral flow
on their coronary angiogram. All patients underwent a to-
tal of 9 shockwave treatments, without any adverse events.
No arrhythmias were noticed during treatment. The most
encountered complaint after treatment was tiredness, which
lasted for a maximum of 24 hours. Furthermore, all patients
returned their questionnaires at baseline and follow-up.
CMR
Baseline and follow-up results are mentioned in Table 2.
There was no significant difference in left ventricular vol-
umes and ejection fraction between baseline and follow-
up results. We did not find a significant difference in the
myocardial perfusion ratio index, which is the relative ra-
tio of the maximum upslope of stress to rest normalised
to left ventricle input: 0.79 ± 0.11 vs 0.72 ± 0.24 (p =
0.40). For analysis of the myocardial perfusion ratio index
the left ventricle was divided into a base, mid and apical
part during analysis using CMR and each part contained 12
segments, in total 36 segments per patient. In one patient
the left ventricular base images during follow-up were not
suitable for analysis. Therefore, a total of 276 segments
out of the initially available 288 segments (= 96 %) were
analysed. Based on visual inspection, a total of 77 seg-
ments were marked as ischaemic segments and received
treatment. Also, when group comparison was performed
between the 77 treated and 199 untreated segments based
on the myocardial perfusion ratio index there was no sig-
nificant difference: 0.80 ± 0.22 vs 0.76 ± 0.31 (p = 0.42).
Secondary endpoints
Neither NYHA class or frequency of nitroglycerin showed
a significant improvement in patients analysed with CMR
(p = 0.102 and p = 0.480, respectively). Although, a trend
to NYHA class improvement was observed after treatment.
When the total group of 15 patients was analysed, as
shown in Fig. 2, we found a significant improvement in
NYHA class and reduction in nitroglycerin use (p = 0.034
and p = 0.012 respectively). Frequency of chest pain did
not show a significant improvement (p = 0.405).
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Fig. 2 Effect of shockwave therapy on NYHA class (a), nitroglycerin use (b), and chest pain frequency (c). Y-axis shows frequency per week
for nitroglycerin use and chest pain frequency. Results are shown as mean ± SD
Discussion
To our knowledge, this is the first quantitative study ex-
amining the effect of shockwave therapy on myocardial is-
chaemia and perfusion. As has been shown previously, our
patients also experienced an improvement in NYHA class
and reduction in nitroglycerin use (Fig. 2). Nevertheless,
in contrast to earlier studies, using qualitative analysis, we
could not demonstrate an improvement in myocardial per-
fusion. Therefore, NYHA class improvement and reduction
in nitroglycerin use could not be explained solely by im-
provement of myocardial perfusion after treatment [11–14].
Table 3 summarises the studies performed thus far using
shockwave therapy to treat refractory angina pectoris pa-
tients. One can observe the diverse treatment strategies used
and difference in time to analysis. In the study performed
by Fukumoto et al., patients underwent further treatment
based on SPECT, resulting in severe bias [11]. Vasyuk
et al., Yang et al. and Prasad et al. had similar study proto-
cols to ours. In contrast to our results, they did demonstrate
improvement in perfusion after different follow-up periods,
either early (1 month) or late (3–9 months) after completion
of shockwave therapy [13–15]. This might be explained by
the fact that we used CMR in contrast to others who used
SPECT, where CMR has been demonstrated in the past to
be superior regarding perfusion measurement in myocar-
dial ischaemia in general and distinguishing between epi-
cardial and endocardial perfusion in particular, compared
with SPECT, due to its higher spatial resolution [19]. Fur-
thermore, it also reliably identifies perfusion abnormalities
when compared with PET and coronary angiography [20].
A placebo-controlled trial performed with more frequent
CMR analysis during follow-up would overcome this issue
in future studies. The difference in results of our and ear-
lier performed studies also reveals a potential lack in our
knowledge of the exact working mechanism of shockwave
therapy.
Nishida et al. studied the effect of extracorporeal shock-
wave in an in vivo pig model [9]. Using real-time poly-
merase chain reaction and Western blotting they demon-
strated an increased upregulation of VEGF in pigs receiving
treatment. Furthermore, they showed an increase in visible
coronary arteries, capillary density (using factor VIII stain-
ing), and regional myocardial blood flow. As the authors
mention, the exact mechanism remains to be elucidated.
Furthermore, it is unknown whether a chronic myocardial
ischaemia model of 4 weeks in an otherwise healthy pig
can be compared with chronic ischaemia of several months
to years in our patients with multiple comorbidities, which
might have an effect on biological mechanisms.
Another important issue to take into consideration is
treatment of viable tissue, which was shown in another
study from the same group [10]. They demonstrated an ef-
fect of shockwave on further improvement of left ventricu-
lar remodelling after acute myocardial infarction. However,
this effect was only observed in patients treated shortly after
myocardial infarction. As they did not observe a significant
effect when treatment was started several weeks after my-
ocardial infarction, this stresses the importance of viable
tissue for shockwave therapy to create an effect. To ensure
that we treated viable, ischaemic tissue 2 experienced CMR
observers located the ischaemic zones.
Evidently, our study is limited by the small sample size
and the lack of a placebo control group. Furthermore, ex-
act quantification of the ischaemic zone using MRI proved
difficult, since part of the treated zone contained healthy
segments in order to be sure the entire ischaemic zone re-
ceived treatment. Therefore, we divided each plane into 12
segments to perform the quantification and minimise the
effect of artifacts and large segments which received min-
imal treatment. Consequently, possible damage of these
treated healthy segments cannot be excluded. Although
we obtained good quality images in all patients, we did
experience motion artifacts due to breathing during perfu-
sion imaging, which might result in ghosting and therefore
influence our measurements [21]. To acquire the best thera-
peutic strategy using shockwave in patients with refractory
angina pectoris, a better understanding of the exact work-
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Table 3 Overview of studies
performed with shockwave
therapy and use of treatment
schedule and time to analysis
Authors Treatment schedule Time to analysis Results
Fukumoto et al. [11] Based on SPECT
results




dial perfusion, CCS class
and reduction of NTG
use, lasting 12 months
Schmid et al. [12] 9 treatments in
3 months




Vasyuk et al. [13] 9 treatments in
3 months





Yang et al. [14] 9 treatments in
3 months





Prasad et al. [15] 9 treatments in
3 months





CCS Canadian Cardiovascular Society; NTG nitroglycerin; LVEF left ventricular ejection fraction
ing mechanism plays a pivotal role. We would therefore
suggest going back to bench to perform in vitro and animal
studies to elucidate the exact working mechanism, thereby
revealing which patients may benefit from this treatment
option, prior to performing placebo-controlled trials.
In conclusion, our study demonstrates that shockwave
therapy improved NYHA functional class and reduced ni-
troglycerin use in our patient group. However, as we did
not observe any improvement in CMR-measured myocar-
dial perfusion and subsequent ischaemic burden, the re-
sponsible mechanisms need to be elucidated.
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